Purpose Preliminary studies suggested that
telotristat ethyl, a
tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with
carcinoid syndrome. This placebo-controlled phase III study evaluated
telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose
somatostatin analog
therapy received (1:1:1) placebo,
telotristat ethyl 250 mg, or
telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received
telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81 for
telotristat ethyl 250 mg ( P < .001) and ‒0.69 for
telotristat ethyl 500 mg ( P < .001). At week 12, mean BM frequency reductions per day for placebo,
telotristat ethyl 250 mg, and
telotristat ethyl 500 mg were -0.9, -1.7, and -2.1, respectively. Responses, predefined as a BM frequency reduction ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo,
telotristat ethyl 250 mg, and
telotristat ethyl 500 mg, respectively. Both
telotristat ethyl dosages significantly reduced mean urinary
5-hydroxyindole acetic acid versus placebo at week 12 ( P < .001). Mild
nausea and asymptomatic increases in gamma-glutamyl
transferase were observed in some patients receiving
telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with
carcinoid syndrome not adequately controlled by
somatostatin analogs, treatment with
telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary
5-hydroxyindole acetic acid.